WASHINGTON — A second Trump administration would bring a new wave of health policy officials into power in Washington. But many of those faces may be familiar.
Aides and administration officials who shaped former President Trump’s most impactful health policy initiatives, from price transparency to prescription drug pricing to banning surprise medical bills, have scattered to think tanks and consulting firms. If Trump wins the election in November, they could be poised for a return.
Given Trump has few deeply held convictions about health care policy and the Republican Party’s platform has precious few details about its plan for the future, Trump’s potential selection of a team to run health agencies will have an outsize impact on his administration’s direction.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect